Secondary Prevention of Stroke — New Trials

Stroke — Office of Health Economics 1988 No 89 London.

Forbes C D (1997) Unpublished research.

Bath P Stroke Therapy: Advances in Commercial opportunities. Connect Pharma Ltd, Oxford Science Pubs, 1995 Oxford UK.

UK-TIA Study Group. United Kingdom Transient Ischaemic Attack (UK-TIA) aspirin trial: final results J Neurology Neurosurgery and Psychiatry 1995; 54: 1044–54.

SALT Collaborative Group. Swedish Aspirin Low dose Trial (SALT) of 75mg of aspirin as secondary prophylaxis after cerebrovascular ischaemic events Lancet 1991; 338, 1345–49.

Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30mg vs 283mg a day) in patients after a transient ischaemic attack or minor ischaemic stroke. N Engl J Med 1991; 325, 1261–66.

Antiplatelet Trialist's a Collaboration. Collaborative overview of randomised trials of anti-platelet therapy-1: prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994; 308:81–105.

Barnett H J M Ebasziw M Meldrum HE . Drugs and surgery in the prevention of ischaemic stroke. N Engl J Med, 1995; 332: 238–48.

Algra A van Gijn J . Aspirin at any dose above 30mg offers only modest protection after cerebral ischaemia Journal of Neurology, Neurosurgery and Psychiatry 1996; 60, 197–99.

Diener H Cunha L Forbes C Sivenius J Smets P Lowenthal A . European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. Journal of Neurological Sciences, 1996; 143, 1–13.

Caprie Steering Committee. A randomised blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) Lancet 1996; 348: 1329–39.

Muller T H Su CAPF Weiserberger H Brickyl R Nehmiz G Eisert W G . Dipyridmole alone or combined with low-dose acetylsalcylic acid inhibits platelet aggregation in human whole blood ex vivo. British Journal of Clinical Pharmacology, 1990; 30: 179–186.